Clinical Trial

Treatment With ABT-199 (Venetoclax) and Purine Analogues in Relapsed/Refractory Acute Myeloid Leukemia

Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 18, 2022 (before its estimated December 2024 completion). Its status may not reflect the trial's current state.
Summary
Non-commercial, open-label interventional phase Ib study to assess the effectivity of the combination of venetoclax and 6-mercaptopurine in patients with relapsed or refractory AML.
Trial Details
NCT Number NCT05506332
Lead Sponsor University Hospital, Antwerp
Conditions Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Enrollment 10 participants
Start Date 2022-07-15
Primary Completion 2024-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2022-08-18